Odomzo (sonidegib) — Highmark
locally advanced basal cell carcinoma (laBCC)
Initial criteria
- age ≥ 18 years
- Diagnosis of locally advanced basal cell carcinoma (ICD-10: C44.01-C44.92)
- Member has experienced recurrence following surgery or radiation therapy OR member is not a candidate for surgery or radiation therapy
Reauthorization criteria
- Prescriber attests that the member is tolerating therapy and has experienced a therapeutic response defined as disease improvement or delayed disease progression
Approval duration
12 months